A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens
of CAM2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic PLD,
either isolated as in autosomal dominant PLD (ADPLD) or associated with autosomal dominant
polycystic kidney disease (ADPKD).
In the Treatment Period of the trial, participants will be allocated at random to 1 of the 3
treatment arms in a 1:1:1 ratio. After completing the Treatment Period (53 weeks)
participants may proceed to a 24-week open-label extension part of the trial and then only
receive the same CAM2029 treatment.
The active ingredient in CAM2029, octreotide, is administered as a subcutaneous depot using
Camurus' FluidCrystal® technology.